Jun 01, 2020 7:00am EDT Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
May 28, 2020 7:00am EDT Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
May 21, 2020 7:00am EDT Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
May 18, 2020 7:00am EDT Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
May 15, 2020 7:00am EDT Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
Apr 14, 2020 7:00am EDT Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Apr 13, 2020 6:30am EDT Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Apr 07, 2020 9:00am EDT Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
Mar 30, 2020 7:00am EDT Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
Mar 27, 2020 7:00am EDT Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
